Clinical trials: Leucovorin
Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease.
- Conditions
- Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
- Trial name
- NCT01964755
- Testing
- Doxorubicin, Methotrexate, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
This phase I trial is to find out the best dose, possible benefits, and/or side effects of riluzole and how well it works in combination with standard of care mFOLFOX6 and bevacizumab in treating patients with colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT04761614
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ning Jin
Colorectal Cancer Metastatic
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for…
- Trial name
- NCT04169347
- Testing
- Oxaliplatin
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Criterium, Inc.
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with leucovorin and fluorouracil in treating young patients with advanced solid tumors.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00281944
- Testing
- oxaliplatin, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Extranodal NK/T-cell Lymphoma
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma.
- Trial name
- BRIDGE-NK (NCT07678229)
- Testing
- GELAD regimen, MEDA regimen, LEAP regimen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Rong Tao
Lymphoma
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002557
- Testing
- CHOP regimen, doxorubicin hydrochloride, etoposide
- Where
- South Africa
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric (Stomach) Cancer
Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or…
- Conditions
- Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Trial name
- OMEC-5 (NCT07000253)
- Testing
- Chemotherapy, Targeted Systemic Therapy, Immunotherapy
- Where
- 5 sites in Netherlands, Norway and 1 more
- Volunteers
- 290 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could improve response rate and resectability rate of liver metastases and survival in colorectal liver metastases (CRLM).
- Trial name
- NCT04687631
- Testing
- mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Fudan University
Colonic Diseases, Adenocarcinoma
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer
Based on the astonishing high response rate in metastatic colorectal cancer in weekly high dose 5-FU and leucovorin, we will conduct a clinical trial to clarify the activity of this regimen in the adjuvant setting.
- Trial name
- NCT00201331
- Testing
- leucovorin+5-FU
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- National Health Research Institutes, Taiwan
mCRC
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal…
- Trial name
- NCT03567629
- Testing
- Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
There is an unmet medical need to treat people with advanced cancer in the stomach and the junction area where the stomach joins the food pipe.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07829757
- Testing
- Zolbetuximab, Oxaliplatin, Folinic Acid
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Cancer
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
Treatment with FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) can be effective, but it has serious side effects, which may require hospitalization.
- Trial name
- NCT02705300
- Testing
- Irinotecan 165 mg/m2 iv, Oxaliplatin 85 mg/m2 iv, Calcium folinate 200 mg/m2 iv
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Vejle Hospital
Healthy Participants
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.
- Trial name
- NCT05615012
- Testing
- BMS-986322, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Although FOLFIRINOX regimen was recently presented to be effective as adjuvant chemotherapy for resectable pancreatic cancer in selected patients who have good physical condition, there is still insufficient evidence on this…
- Trial name
- NCT04084496
- Testing
- Folfirinox
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease
MRD in PAAD Adjuvant Therapy
Our preliminary research has explored the detection efficacy of minimal residual disease (MRD) in pancreatic cancer. In patients with pancreatic cancer undergoing dual-agent adjuvant chemotherapy, the median recurrence-free…
- Conditions
- The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy
- Trial name
- NCT06867146
- Testing
- Three-drug chemotherapy group, two-drug chemotherapy group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Neoplasms
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells.
- Trial name
- NCT07277270
- Testing
- GSK5764227, Bevacizumab, Fluorouracil
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003422
- Testing
- fluorouracil, leucovorin calcium, adjuvant therapy
- Where
- 9 sites in Canada, United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Medical Research Council
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Cancer
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer
GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous pelvic radiotherapy for the primary rectal cancer.
- Trial name
- GRECCAR15 (NCT03879109)
- Testing
- Chemotherapy FOLFIRINOX, 6 cycles, Radiochemotherapy, Surgery
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- University Hospital, Bordeaux
Gastroesophageal Adenocarcinoma
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.
- Trial name
- RESTAGE (NCT07625930)
- Testing
- FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab
- Where
- Canada
- Volunteers
- 184 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.